Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) – the world’s largest, fully-integrated, musculoskeletal (MSK) value-based care and outcomes management company. This collaboration will focus on enhancing solutions for ASC customers, physicians, and their patients through HOPCo’s digital health and analytics platforms, myrecovery® and Vitals®

The partnership with HOPCo provides a comprehensive technology platform that encompasses all musculoskeletal procedures performed in the ASC segment. The AI-powered myrecovery platform enhances the clinical experience by utilizing patient engagement tools such as remote care management, real time communications, and remote therapeutic monitoring (RTM), while providing critical* quality outcome metrics through proprietary activity tracking technology, functional outcomes reporting, patient-reported outcomes (PROMs), and longitudinal data integration across a patient’s care journey. HOPCo’s Vitals platform provides tools, analytics, and dashboards to help Smith+Nephew customers deliver better, more efficient and coordinated care while also meeting value-based care requirements aiming to reduce cost.


'We are thrilled to partner with HOPCo and the ability to bring their innovative digital solutions to customers in the ASC across both our Orthopaedic and Sports Medicine businesses. The HOPCo solutions will allow our customers to unlock value in the ASC be it through the use of RTM, PROMs, or leveraging analytics to drive efficiencies. Their commitment to driving meaningful change in outcomes through data aligns perfectly with the strength and value of the CORI Surgical System,' said Craig Gaffin, President of Global Orthopaedics at Smith+Nephew. 'This collaboration underscores our commitment to advancing orthopaedic surgery through innovative technology, improving patient outcomes, and transforming the future of healthcare.'

Data from the CORI Surgical System’s ability to perform image-agnostic robotic-assisted knee surgeries will now be augmented with the powerful data-driven insights from HOPCo’s Vitals and AI-powered myrecovery digital solutions. The integrated digital platform will encompass some of the most advanced practice and health system analytics solutions available. Planned integration with Smith+Nephew’s intraoperative data from the CORI Surgical System through RI.INSIGHTS Data Visualization Platform will provide surgeons and healthcare providers with enhanced analytics to link personalized surgical planning, intra-operative decision-making, and PROMS tracking and optimization.

“Smith+Nephew is clearly committed to using outcomes data to enhance the value of its products and services,” said Dr. David Jacofsky, CEO and Chairman at HOPCo. “HOPCo’s myrecovery and Vitals platforms will allow Smith+Nephew to leverage unique longitudinal data to do just that, while simultaneously providing meaningful additional value to customers and improving patient outcomes.”

- ends –

 * https://www.federalregister.gov/documents/2023/11/22/2023-24293/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment


Media Enquiries
Dave Snyder          +1 (978) 749-1440 
Smith+Nephew      david.snyder@smith-nephew.com


About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.


About HOPCo

Healthcare Outcomes Performance Company (HOPCo) is the global leader of integrated musculoskeletal value-based health outcomes management, digital analytics, practice management, and health system service line management. This includes comprehensive expertise across all MSK specialties, including orthopedics, spine, pain management, rehabilitation, neurosurgery, and neurology. HOPCo's integrated care, analytics, and facilities development platforms have proven to increase the quality of patient care while reliably reducing the total cost of MSK care across the care continuum for practices, health systems and payors alike. HOPCo's affiliated payors, practices and health systems successfully participate in highly efficient value-based contracting (bundled payments, population health programs, and other advanced risk-based arrangements) utilizing HOPCo's proprietary platforms, IT solutions, integrated analytics, advanced medical economics and standardized care pathways.  Visit www.hopco.com to learn more.


Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers

THỦ THUẬT HAY

Hướng dẫn sửa lỗi đăng nhập iTunes/ iCloud trên Windows 10

Tìm hiểu qua trên mạng thì cũng có không ít người dùng gặp phải lỗi này với Windows 10, mình cũng đã thử nhiều cách theo gợi ý, xóa đi cài lại các kiểu vẫn không được và cuối cùng giải quyết được vấn đề theo cách đơn

Hướng dẫn kiểm tra và cập nhật phiên bản Adobe Flash Player cho máy tính

Tuy nhiên, ngoài sự tiện dụng đó thì cũng không thể phủ nhận Adobe Flash Player vẫn có những lỗi nghiêm trọng về bảo mật và đang là 'miếng mồi ngon' để kẻ xấu lợi dụng, tấn công người dùng.

ClickLock là gì? Cách bật Mouse ClickLock đơn giản và nhanh chóng trên Windows

Nếu bạn đang sử dụng chuột quá nhiều trên laptop hoặc máy tính để bàn, điều này có thể gây ra sự mệt mỏi vì phải thao tác quá nhiều. Tuy nhiên, bạn có thể giảm thiểu sự mỏi mệt này bằng cách sử dụng tính năng Mouse

Mẹo hay giúp bạn chặn ai đó trong Google Drive, hãy thử ngay

Bạn muốn chặn ai đó trong Google Drive để tránh bị làm phiền từ các email, dịch vụ, các tệp rác chia sẻ nhưng không biết làm thế nào? Trong bài này sẽ hướng dẫn cách để chặn ai đó trong Google Drive thật dễ dàng.

Hướng dẫn cách đặt vé máy bay Vietnam Airlines trực tuyến

Vietnam Airlines là hãng hàng không lớn nhất Việt Nam hiện nay và là hãng hàng không 4 sao duy nhất ở Việt Nam đáp ứng đầy đủ các điều kiện của tiêu chuẩn hàng không thế giới. Chính vì vậy giá vé của Vietnam Airlines

ĐÁNH GIÁ NHANH

Đánh giá pin Meizu M5: 3070mAh trụ được bao lâu ?

Meizu M5 có viên pin 3070mAh. Vậy thời lượng sử dụng thực tế có đáp ứng đủ nhu cầu sử dụng trong một ngày làm việc hay không? Hãy cùng FPTShop khám phá nhé.

Đánh giá camera Redmi Note 4: Có cải thiện nhưng chưa đủ

Chưa bao giờ cơn sốt Xiaomi bước chân vào Việt Nam lại hot đến vậy, điển hình là bài Redmi Note 4 của mình nhận được nhiều sự quan tâm của người...

Đánh giá chi tiết Infinix Note 3: Phablet hoàn hảo 4 triệu

Được ra mắt cùng với chiếc Hot 4, Infinix Note 3 được giao sứ mệnh là chiếc phablet 6 inch tấn công vào phân khúc dưới 4 triệu hiện nay. Thiết kế...